


GSK delivers resilient performance, strong commercial execution and further strategic progress in Q3



All % at constant exchange rates (CER)



Strong performance from key growth drivers partly offset expected disruption from COVID-19. New and specialty pharmaceuticals £2.5 billion, +12% CER

Total group operating margin

21.5%

Adjusted group operating margin

30.8%

Total EPS

25.0p - 9%

Adjusted EPS

35.6p + 1%

3 approvals since Q2 results

Dividend **19p**

"GSK has responded well to a challenging operating environment this year with disciplined cost control and strong commercial momentum in key growth products. R&D delivery has continued with three product approvals since Q2 results and we are urgently advancing possible COVID-19 Solutions with our partners."

Emma Walmsley, CEO, GSK

Journalists/media see press release on www.gsk.com for full details on Q3 2020.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 62 to 64 of the press release.

*Proforma growth: -6%

**Proforma growth: -5%

Respiratory syncytial virus

